Jefferies raised the firm’s price target on Rezolute (RZLT) to $20 from $15 and keeps a Buy rating on the shares. The firm likes the setup heading into the congenital hyperinsulinism pivotal top-line data, because the current market cap implies just below a 2x multiple on the firm’s top peak sales estimate of $540M. The firm added that it believes ersodetug has a $1.1B opportunity in tumor hyperinsulinism and $540M in congenital hyperinsulinism.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Rezolute Approves Key Proposals at Annual Meeting
- Promising Potential of Rezolute’s Ersodetug in Treating Congenital Hyperinsulinism Drives Buy Rating
- Rezolute’s Promising Future: Buy Rating Backed by Strong Financials and Strategic Market Expansion
- Rezolute’s Promising Growth Potential: Buy Rating Backed by Strong Market Prospects for Ersodetug
- Rezolute Highlights Ersodetug Development at Investor Event